Clinical characteristics and response to tyrosine kinase inhibitors of patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations

HFCAS OpenIR

	Clinical characteristics and response to tyrosine kinase inhibitors of patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations
其他题名	Clinical characteristics and response to tyrosine kinase inhibitors of patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations
	2017
发表期刊	CHINESE JOURNAL OF CANCER RESEARCH
ISSN	1000-9604
摘要	Objective: To investigate the clinical features of patients with non-small cell lung cancer (NSCLC) harboring uncommon epidermal growth factor receptor (EGFR) mutations, and the treatment outcomes of EGFR tyrosine kinase inhibitors (TKIs) in these patients.
其他摘要	Objective To investigate the clinical features of patients with non-small cell lung cancer (NSCLC) harboring uncommon epidermal growth factor receptor (EGFR) mutations, and the treatment outcomes of EGFR tyrosine kinase inhibitors (TKIs) in these patients. Methods We retrospectively analyzed the data of 128 NSCLC patients pathologically diagnosed with uncommon EGFR mutation in the Department of Pathology, National Cancer Center Results Among the total 128 patients, 11 patients were non-adenocarcinoma, including squamous carcinoma (3.9%), adenosquamous carcinoma (2.3%), large cell carcinoma (0.8%), and composite neuroendocrine carcinoma (1.6%). Single mutations accounted for 75.0% (96 De novo T790M (0.8%), and T725 (0.8%). Thirty-two patients harbored complex mutations. Forty advanced patients received EGFR-TKI, the objective response rate (ORR) was 20.0%, the disease control rate (DCR) was 85.0%, and the progression-free survival (PFS) was 6.4 95% confidence interval (95% CI), 4.8–7.9 months. The exploratory analysis of tumor response and PFS in 33 patients with G719X De novo T790M experienced rapid disease progression with PFS no more than 2.7 months. Conclusions Uncommon EGFR-mutant NSCLCs are heterogeneous, EGFR-TKIs can have different efficacy in this specific subtype, and thus further individual assessment is required for each case.
关键词	EGFR MUTATIONS GEFITINIB TREATMENT 1ST-LINE TREATMENT OPEN-LABEL RARE MULTICENTER ERLOTINIB GENE CHEMOTHERAPY EFFICACY Non-small cell lung cancer EGFR uncommon mutation target therapy
收录类别	CSCD
语种	英语
资助项目	[Chinese Geriatric Oncology Society (CGOS)]
CSCD记录号	CSCD:5956037
引用统计
文献类型	期刊论文
条目标识符	http://ir.hfcas.ac.cn:8080/handle/334002/62083
专题	中国科学院合肥物质科学研究院
推荐引用方式 GB/T 7714	. Clinical characteristics and response to tyrosine kinase inhibitors of patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations[J]. CHINESE JOURNAL OF CANCER RESEARCH,2017,29.
APA	(2017).Clinical characteristics and response to tyrosine kinase inhibitors of patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations.CHINESE JOURNAL OF CANCER RESEARCH,29.
MLA	"Clinical characteristics and response to tyrosine kinase inhibitors of patients with non-small cell lung cancer harboring uncommon epidermal growth factor receptor mutations".CHINESE JOURNAL OF CANCER RESEARCH 29(2017).